ESR1 and breast cancer: Therefore, by measuring the ER-PR correlated 18 gene signature in a number of highly curated datasets, we have identified a prognostic signature which identifies patients with ER+PR+ breast cancer who are at risk of earlier metastasis, particularly in Luminal B cases, and can thus predict poorer outcome independent of ER or PR status.